They showed notable activity against protein tyrosine phosphatase 1B (PTP1B), and since PTP1B is a promising drug target for type II diabetes and obesity, compounds 354 and 355 may contribute to the treatment of type II diabetes and obesity [109]. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.